Art

J-GLOBAL ID：201502204445097440   Reference number：15A1273950

分子標的治療を含む併用療法 造血器腫瘍における分子標的治療の耐性と併用療法による克服

Author (1)： MINAMI YOSUKE (神戸大 医 病院 輸血・細胞治療部)
Material： がん分子標的治療  (Journal of Molecular Targeted Therapy for Cancer)
Volume： 13  Issue： 3  Page： 346-351  Publication year： Oct. 09, 2015 
JST Material Number： L5138A  ISSN： 1347-6955  Document type： Article
Article type： 解説  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human ,...
Semi thesaurus term： rituximab

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=15A1273950&from=J-GLOBAL&jstjournalNo=L5138A") }}

JST classification (3)： Blood cell tumors(=neoplasms)  (GK04000M) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Substance index (5)： Imatinib ,  Tretinoin ,  Dasatinib ,  Nilotinib ,  Bortezomib

Reference (11)：

• Dean M, Fojo T, Bates S : Tumour stem cells and drug resistance. Nat Rev Cancer 5 275-284, 2005
• Tomita A, Kiyoi H, Naoe T : Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3)in acute promyelocytic leukemia. Int J Hematol 97 717-725, 2013
• Shah NP, Nicoll JM, Nagar B, et al : Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 : 117-125, 2002
• Apperley JF : Part I ; mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8 : 1018-1029, 2007
• Minami Y : Properties of leukemic stem cells and treatment strategy for the cure of chronic myelogenous leukemia. Rinsho Ketsueki 54 : 552-558, 2013

Terms in the title (4)： 分子標的治療 ,  併用療法 ,  造血器腫瘍 ,  耐性